Related Experiment Videos
Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials
1Center for Evidence-Based Medicine, University of Oxford, Oxford, United Kingdom. markolens@aol.com
Purpose:
No standard systemic adjuvant therapy has been proven to increase overall survival in melanoma patients. The effect of interferon alfa (IFNalpha) as a single agent or in combination has been widely explored in clinical trials. The purpose of this study was to assess the benefit of IFNalpha therapy in malignant melanoma.
Methods:
We performed a systematic review of randomized controlled trials comparing regimens with or without IFNalpha adjuvant therapy in melanoma patients. We assessed the effect of IFNalpha therapy on overall survival (OS), disease-free survival (DFS), melanoma recurrences, and toxicity. The quality of each trial was systematically evaluated.
Results:
Nine randomized controlled trials (RCTs) of IFNalpha therapy in melanoma patients were identified. Eight were published and one was unpublished. Eight trials comprising 3,178 patients fulfilled our inclusion criteria and were analyzed. Quality assessment scores ranged from 22 to 71, with a mean score of 55.4 (95% confidence interval, 53.8 to 57.0). For OS, only one trial reported a statistically significant benefit for IFNalpha, but our analysis did not confirm it. Two trials reported statistically significant benefit in DFS for the patients treated with IFNalpha, but our analysis confirmed it in only one trial. There was a wide clinical heterogeneity between included trials, making meta-analysis inappropriate.
Conclusion:
In our review, results from included RCTs demonstrated no clear benefit of IFNalpha therapy on OS in melanoma patients. A large RCT is required to answer whether a full regimen of IFNalpha therapy is effective and to identify the subgroups of patients who might benefit from IFNalpha treatment.
Insights
Interferon alfa (IFNalpha) therapy does not clearly improve overall survival in melanoma patients. Further large randomized controlled trials are needed to determine its effectiveness and identify potential patient subgroups who may benefit from this treatment.
Area of Science:
- Oncology
- Clinical Trials
- Systematic Review
Background:
- Adjuvant systemic therapy for melanoma lacks proven overall survival benefits.
- Interferon alfa (IFNalpha) has been investigated as a potential treatment for melanoma.
Purpose of the Study:
- To systematically review randomized controlled trials (RCTs) evaluating the efficacy of adjuvant interferon alfa (IFNalpha) therapy in melanoma patients.
- To assess the impact of IFNalpha on overall survival (OS), disease-free survival (DFS), recurrence rates, and toxicity.
Main Methods:
- Systematic review of nine randomized controlled trials (RCTs) comparing IFNalpha-containing regimens with control groups.
- Inclusion criteria focused on melanoma patients receiving adjuvant therapy.
- Assessment of trial quality and analysis of outcomes including OS, DFS, and toxicity.
Main Results:
- Eight RCTs with 3,178 patients were analyzed, exhibiting significant clinical heterogeneity.
- IFNalpha therapy did not demonstrate a statistically significant benefit for overall survival (OS) across the analyzed trials.
- While some trials suggested benefits in disease-free survival (DFS), the analysis confirmed this in only one trial.
Conclusions:
- Current evidence from RCTs does not support a clear benefit of interferon alfa (IFNalpha) therapy for improving overall survival in melanoma patients.
- A large-scale RCT is necessary to definitively establish the efficacy of IFNalpha regimens.
- Identifying specific patient subgroups who might benefit from IFNalpha treatment requires further investigation.